Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Non-cash Items (2016 - 2025)

Coherus Oncology's Non-cash Items history spans 12 years, with the latest figure at $18.2 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 1951.45% year-over-year to $18.2 million; the TTM value through Dec 2025 reached $18.2 million, up 1951.45%, while the annual FY2025 figure was $18.2 million, 1951.45% up from the prior year.
  • Non-cash Items for Q4 2025 was $18.2 million at Coherus Oncology, up from $889000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $61.4 million in Q4 2021 and bottomed at $889000.0 in Q4 2024.
  • The 5-year median for Non-cash Items is $37.4 million (2023), against an average of $33.9 million.
  • The largest annual shift saw Non-cash Items crashed 97.62% in 2024 before it soared 1951.45% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $61.4 million in 2021, then decreased by 16.12% to $51.5 million in 2022, then fell by 27.38% to $37.4 million in 2023, then plummeted by 97.62% to $889000.0 in 2024, then skyrocketed by 1951.45% to $18.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Non-cash Items are $18.2 million (Q4 2025), $889000.0 (Q4 2024), and $37.4 million (Q4 2023).